Product Description
Adefovir is used to treat chronic (long-term) hepatitis B infection (swelling of the liver caused by a virus) in adults and children 12 years of age and older. Adefovir is in a class of medications called nucleotide analogs. It works by decreasing the amount of hepatitis B virus (HBV) in the body.
Mechanisms of Action: NRT Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Brazil | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Italy | Japan | Jordan | Korea | Latvia | Lithuania | Luxembourg | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Saudi Arabia | Singapore | Slovakia | Slovenia | Spain | Sweden | Taiwan | Thailand | Turkey | United Kingdom | United States | Venezuela | Vietnam
Approved Indications: None
Company: Gilead Sciences
Company Location: Western America
Company Founding Year: 1987
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 4
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Hepatitis B, Chronic
Phase 1: Healthy Volunteers|Ischemic Stroke|Pain Unspecified
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
CTR20260615 |
CTR20260615 | P1 |
Completed |
Ischemic Stroke |
2026-03-28 |
2026-05-30 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
CTR20251544 |
CTR20251544 | P1 |
Completed |
Pain Unspecified|Healthy Volunteers |
2025-05-14 |
2025-05-17 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
CTR20150224 |
CTR20150224 | P1 |
Recruiting |
Hepatitis B, Chronic |
None |
2025-04-29 |
Patient Enrollment|Treatments|Trial Status |
|
CTR20132851 |
CTR20132851 | P3 |
Active, not recruiting |
Hepatitis B, Chronic |
None |
2025-04-29 |
Patient Enrollment|Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
02/10/2026 |
News Article |
Gilead Sciences Announces Fourth Quarter and Full Year 2025 Financial Results |
|
10/30/2025 |
News Article |
Gilead Sciences Announces Third Quarter 2025 Financial Results |
|
08/07/2025 |
News Article |
Gilead Sciences Announces Second Quarter 2025 Financial Results |
|
04/24/2025 |
News Article |
Gilead Sciences Announces First Quarter 2025 Financial Results |